8-K

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934

DATE OF REPORT (Date of Earliest Event Reported) — August 26, 2008

COLUMBIA LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

Commission File No. 1-10352

Delaware	59-2758596
(State of Incorporation)	(I.R.S. Employer
	Identification No.)
354 Eisenhower Parkway
Livingston, New Jersey	07039
(Address of principal	Zip Code
executive offices)

Registrant’s telephone number, including area code: (973) 994-3999

     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Table of Contents

8-K — FORM 8-K — CURRENT REPORT

 EX-99.1: PRESS RELEASE

ITEM 8.01. OTHER EVENTS.

     On August 26, 2008, Columbia Laboratories, Inc. (the “Company”), issued a press release announcing that the Company closed on the sale of a total of 1,333,000 shares of its common stock, at a price of $3.50 per share, with certain investors in connection with a registered direct offering of the Company’s common stock. Net proceeds to the Company from the sale of the common stock in the offering totaled approximately $4,105,975. All of the shares of common stock were offered pursuant to an effective Registration Statement on Form S-3 filed with the Securities and Exchange Commission on May 31, 2000, which was declared effective on June 30, 2000.

     A copy of the press release is being filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

     (d) Exhibits.

Exhibit No.	Description
99.1	Press release dated August 26, 2008

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 26, 2008

COLUMBIA LABORATORIES, INC.
By:	/s/ James A. Meer
	James A. Meer
	Senior Vice President, Chief Financial Officer & Treasurer

Exhibit Index

Exhibit No.	Description
99.1	Press release dated August 26, 2008

EX-99.1

Exhibit 99.1

354 Eisenhower Parkway
Plaza I, Second Floor
Livingston, NJ 07039
  
TEL: (973) 994-3999
FAX: (973) 994-3001

NEWS

COLUMBIA LABORATORIES CLOSES
REGISTERED DIRECT COMMON STOCK OFFERING

LIVINGSTON, NJ— August 26, 2008—Columbia Laboratories, Inc. (Nasdaq: CBRX) has raised approximately $4.7 million in gross proceeds to the Company through the sale of approximately 1.3 million shares of its common stock at a price of $3.50 per share in a registered direct offering. Net proceeds are expected to be approximately $4.1 million after offering-related fees and expenses. Columbia intends to use the net proceeds from the offering for general corporate purposes, including funding its clinical development and other research and development activities, internal and/or collaborative sales, marketing and distribution expenditures, capital expenditures and working capital needs.

The shares were offered pursuant to an effective registration statement previously filed with the Securities and Exchange Commission. The Benchmark Company, LLC served as placement agent for the transaction. The shares of common stock were offered by means of a prospectus and accompanying prospectus supplement, a copy of which can be obtained from The Benchmark Company, LLC, 40 Fulton Street, 19th Floor, New York, NY 10038, or by calling (800) 207-7455.

An electronic copy of the prospectus supplement will also be available on the website of the Securities and Exchange Commission (the “SEC”) at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sales of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Columbia Laboratories

Columbia Laboratories, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the women’s healthcare and endocrinology markets that use its novel bioadhesive drug delivery technology. Columbia markets CRINONE^® 8% (progesterone gel) and PROCHIEVE^® 8% (progesterone gel) in the United States for progesterone supplementation as part of an Assisted Reproductive Technology treatment for infertile women with progesterone deficiency. The Company also markets STRIANT^® (testosterone buccal system) for the treatment of hypogonadism in men. The Company’s partners market CRINONE^® 8%, STRIANT^®, and three other products to additional U.S. and foreign markets. The Company’s research and development programs include the PREGNANT (PROCHIEVE^® Extending GestatioN A New Therapy) Study of PROCHIEVE^® 8% to reduce the risk of preterm birth in women with a short cervix at mid-pregnancy and a vaginal lidocaine product to prevent and treat dysmenorrhea. For more information, please visit www.columbialabs.com.

Page 1 of 2

Columbia Laboratories Closes Registered Direct Common Stock Offering	Page 2 of 2
August 26, 2008

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements about Columbia Laboratories, Inc.’s expectations, including, without limitation, the intended use of proceeds and the future clinical and other development of, and potential applications for, the Company’s product candidates. Such forward-looking statements involve certain risks and uncertainties; actual results may differ materially from those projected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. Factors that might cause future results to differ include, but are not limited to, the following: the successful marketing of CRINONE^® 8% (progesterone gel), PROCHIEVE^® 8% (progesterone gel), and STRIANT^® (testosterone buccal system) in the U.S.; the timely and successful development of new products, including vaginal lidocaine to prevent and treat dysmenorrhea, and new indications for current products, including PROCHIEVE^® 8% to reduce the risk of preterm birth in women with a short cervix in mid-pregnancy; the timely and successful completion of clinical studies, including the clinical studies of our vaginal lidocaine product candidate and the ongoing Phase III PREGNANT (PROCHIEVE^® Extending GestatioN A New Therapy) Study of PROCHIEVE^® 8% in short cervix patients; success in obtaining acceptance and approval of new products and new indications for current products by the FDA and international regulatory agencies; the impact of competitive products and pricing; competitive economic and regulatory factors in the pharmaceutical and healthcare industry; general economic conditions; and other risks and uncertainties that may be detailed, from time-to-time, in Columbia’s reports filed with the Securities and Exchange Commission. Columbia Laboratories undertakes no obligation to publicly update any forward-looking statements.

###

Contact:
James A. Meer, Senior Vice President, CFO & Treasurer
Columbia Laboratories, Inc.
(973) 486-8860

Melody A. Carey, Co-President
Rx Communications Group, LLC
(917) 322-2571